Sosei’s Heptares unit has won another big pharma deal with Pfizer calling on the UK membrane protein specialist to help it identify potential drugs.
UK drugmakers have a lot to gain from additional investment in robotic production technologies according to Barclays.
Pfizer says it will decide in 2018 whether to split its generics and branded businesses but M&A experts are already predicting how the giant will get rid of its established drugs programme.
Hefei will manufacture the API for Oramed's oral insulin tablet as part of a potential $50m licensing deal in China, Hong Kong and Macau.
ManKind Pharma plans to set up manufacturing facilities in Northeast India to bring production in-house and cut its tax bill.
In-Pharmatechnologist.com's round-ups of the industry's latest clinical and executive hires.